SEMA4D and neoplasm: Finally, as SEMA4D is a novel prognostic indicator in Group 3 and Group 4 patients, is associated with a decrease in self‐renewal, and growth and is an upstream regulator of RHO activity, we evaluated the effect of this candidate gene on tumor growth in vivo.